Switching bipolar disorder patients treated with clozapine to another antipsychotic medication: a mirror image study

Petru Iftene¹,²
Andreea Teodorescu¹,²
Marius Alexandru Moga¹
Alina Mihaela Pascu¹
Roxana Steliana Miclaus¹,²
¹Faculty of Medicine, Transilvania University of Brasov, Brasov, Romania;
²Clinical Hospital of Psychiatry and Neurology Brasov, Brasov, Romania

Abstract: Bipolar disorder (BD) is associated with periodic symptom exacerbations, leading to functional impairment, and increased risk of suicide. Although clozapine has never been approved for the treatment of BD, it is occasionally used in severe mania. The aim of the study is to evaluate the risks and benefits of switching clozapine in remitted BD patients. This is an observational, mirror image study of 62 consecutive remitted BD outpatients treated with clozapine. Twenty-five patients were switched to another antipsychotic following a change in a drug reimbursement rule, while 37 continued on clozapine. The mean time in remission was shorter for the switched group (9.2 ± 4 months vs 13 ± 6 months, P = 0.018), and the number of patients who relapsed was larger (n = 21 vs n = 8, P < 0.001). The results suggest that switching from clozapine to another antipsychotic may increase the risk of relapses in remitted patients with BD.

Keywords: clozapine, bipolar disorder, relapse, switch, cost

Background
Bipolar disorder (BD) is associated with recurrent exacerbation of manic, depressed or mixed episodes, leading to functional impairment, substance abuse, risk of suicide, accidents, and increased cost of care.¹–⁶ Antipsychotics are a proven option in the treatment of BD.⁷–¹¹ Although clozapine has never been approved for the treatment of bipolar disorder, it has showed efficacy in acute mania with psychosis and for the treatment of refractory symptoms associated with BD.¹²–¹⁶

The efficacy of clozapine in severe manic patients was reported both as monotherapy and as an add-on strategy.¹⁷ Despite this evidence, clozapine remains underutilized in general¹⁸ and in BD in particular, mostly due to tolerability and safety concerns.¹⁹

The aim of the study was to evaluate the risks and benefits of switching from clozapine to another antipsychotic medication in BD patients with remitted manic, depression, or mixed episodes. The study took advantage of a change in local reimbursement rules which started in 2014, the cost of clozapine was no longer reimbursed for patients with a diagnosis of BD disorder. This naturalistic study was conducted in the 3rd Clinical Department of Clinical Hospital of Psychiatry and Neurology, Brasov, Romania (an academic unit), according to Good Clinical Practice rules and local regulations. The study was approved by the local Ethics committee (Comisia de Etica). Written informed consent has been obtained from all patients for participation in this study.
Methods

Study design

This is an observational, naturalistic, mirror image study of a cohort of 62 consecutive BD outpatients in remission after severe manic episode treated with clozapine between 2012 and 2014. Clozapine was administered and adverse effects were monitored according to local and international guidelines. Since clozapine never received a regulatory indication for the treatment of BD, in an attempt to control pharmacy costs, in 2014 the health insurance authorities in Romania discontinued reimbursement of clozapine costs for BD patients.

Upon reimbursement discontinuation in 2014, it was explained to patients and their families by the treating psychiatrist that in order to continue treatment with clozapine they would have to pay between 30 €/month (200 mg/day) and 90 €/month (600 mg/day) or be switched to another antipsychotic. The risks and the potential benefits of the switch to another antipsychotic were also explained.

Twenty-five patients (40%) opted to switch to another antipsychotic and the rest remained on clozapine. All switched patients were tapered during a 4 week period. In the switched group the first choice for replacing clozapine was quetiapine (n=10, 40%) with a mean dose of 640 mg/day (average between 400–800 mg/day). The rest of the antipsychotics used for switching are presented in Table 1. In both groups (switched and non-switched), the augmentation of antipsychotic treatment included: mood stabilizers (sodium valproate), benzodiazepines (diazepam and lorazepam), hypnotics (zopiclone, zolpidem, clonazepam, and nitrazepam), and/or addition of a second antipsychotic (haloperidol and levomepromazine). The patients were evaluated with the help of Young Mania Rating Scale (YMRS),20 Montgomery–Åsberg Depression Rating Scale,21 and Clinical Global Impression for Bipolar Disorder (CGI-BP)22 by two board-certified psychiatrists. The socioeconomic status was also evaluated and data included the total income per family, number of rooms per person, and the number of persons who supported the patient’s treatment.

### Statistical analysis

Demographics and severity scores before and after clozapine switching were compared using the variance ratio test (F-test). Statistical significance was set at two-sided P<0.05.

### Results

Of the 62 patients included in this study, 37 (59.7%) continued clozapine (non-switched group). The rest, 25 (40.3 %), were switched to another antipsychotic (switched group). Demographics and results of the switch are shown in Table 2. The mean score of CGI-BP at admission in study was similar in both groups (2.3 vs 2.4, respectively). After switching, a significant proportion of patients relapsed (n=21.0, 84.0%), 13 men and 8 women. In all cases the relapse episode was manic and patients required hospitalization. The mean YMRS score at relapse was significantly higher compared with the evaluation at the time prior to switching (31.78 standard deviation [SD]=9.72 vs 11.99 SD=7.29, P<0.01). As shown in the Table 2 more switched patients were hospitalized and exacerbated than patients who continued on clozapine.

According to the local prescribing protocol for BD, the patients were switched to: olanzapine, quetiapine, risperidone, aripiprazole, and haloperidol. One patient continued treatment with amisulpride. The antipsychotics used after clozapine switching are presented in Table 2. There was no statistical difference between second generation antipsychotics (SGAs) and haloperidol regarding the time until relapse or in the SGAs group. The decision to switch to a specific antipsychotic was made by the psychiatrist based on his individual preference.

### Discussion

The major finding of this study was that replacing clozapine with another antipsychotic might lead to an increased risk in relapse and hospitalization in remitted BP patients.

The use of clozapine on- and off-label and the apparent under-utilization of clozapine remains a controversial issue in clinical psychiatry.18 Besides treatment-resistant schizophrenia, the only other indication approved by regulatory authorities (US Food and Drug Administration) for clozapine is for suicide prevention in schizophrenia.23 Nevertheless, and despite the lack of randomized controlled studies, clozapine is used off-label for the treatment of aggression in patients with BD, intermittent explosive disorder, post-traumatic stress disorder mental retardation, manifestations of personality disorder and agitation in dementia.16,24–31 Furthermore, clozapine use reduced psychiatric hospitalization and emergency room visits, numbers and length of psychiatric admissions, and psychotropic comedictions, in patients with BD.15,32

### Table 1 The antipsychotics used for switching

<table>
<thead>
<tr>
<th>Antipsychotics</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol</td>
<td>4 (19.04)</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>3 (14.28)</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>10 (47.61)</td>
</tr>
<tr>
<td>Risperidone</td>
<td>2 (9.52)</td>
</tr>
<tr>
<td>Amisulpride</td>
<td>1 (4.76)</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>1 (4.76)</td>
</tr>
</tbody>
</table>
Table 2 Patient demographics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Non-switched group</th>
<th>Switched group</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, male, n=36, 58.1%</td>
<td>23</td>
<td>13</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Age (years)</td>
<td>38.94 (10.59)</td>
<td>38.76 (10.17)</td>
<td>0.846</td>
</tr>
<tr>
<td>Age of onset (years)</td>
<td>26.67 (8.17)</td>
<td>27.60 (7.71)</td>
<td>0.782</td>
</tr>
<tr>
<td>Duration of illness (years)</td>
<td>12.00 (7.68)</td>
<td>11.16 (5.51)</td>
<td>0.091</td>
</tr>
<tr>
<td>Number of hospitalizations (lifetime)</td>
<td>81.67 (5.38)</td>
<td>7.60 (3.65)</td>
<td>0.049</td>
</tr>
<tr>
<td>Days of hospitalizations (lifetime)</td>
<td>212.56 (123.90)</td>
<td>190.20 (90.76)</td>
<td>0.113</td>
</tr>
<tr>
<td>Clozapine before reoccurring, months, mean (SD)</td>
<td>13.91 (6.20)</td>
<td>14.32 (5.27)</td>
<td>0.408</td>
</tr>
<tr>
<td>Remission before clozapine discontinuation (months)</td>
<td>10.18 (5.55)</td>
<td>10.64 (4.58)</td>
<td>0.326</td>
</tr>
<tr>
<td>Remission after clozapine discontinuation (months)</td>
<td>12.93 (6.24)</td>
<td>9.24 (3.90)</td>
<td>0.018</td>
</tr>
<tr>
<td>Relapse after clozapine replacing</td>
<td>8 (21.62)</td>
<td>21 (77.77)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hospitalization after clozapine replacing</td>
<td>8 (24.24)</td>
<td>25 (75.76)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Total amount of money/family</td>
<td>€780</td>
<td>€821</td>
<td>0.884</td>
</tr>
<tr>
<td>Number of persons who support patient’s treatment</td>
<td>2.3</td>
<td>2.1</td>
<td>0.921</td>
</tr>
</tbody>
</table>

Note: Data presented as n (%) unless stated otherwise.

**Conclusion**

As we know, besides psychotropic medication, many other factors influence illness course and relapse, and many of these are related to socioeconomic circumstances. Switching antipsychotic could be one of these factors (type of switch, low doses, too fast or too slow tapering, less sedative effect for aripiprazole or risperidone, etc.). In our study there was no difference in the total amount of income per family as well as the number of relatives who supported the cost of patient’s treatment.

The current study has limitations which are inherent to the naturalistic, non-randomized design, such as the possibility that the patients’ and their families’ decision not to discontinue clozapine was determined by a perceived likelihood of impending exacerbation which might have affected the outcome. Furthermore, in addition to antipsychotics both groups were treated with additional but different psychotropics, which in turn might have also affected the outcome. Moreover, despite the gradual discontinuation of clozapine, a cholinergic rebound might have occurred in some of the patients.31

**Acknowledgments**

We would like to thank to the staff of the Clinical Hospital of Psychiatry and Neurology Brasov, România, and to Gheorghe Pamfil for assistance with data collection and processing.

**Authors’ contributions**

Conception and design of the research, PI and AT; acquisition of data, PI and AT; analysis and interpretation of the data, PI, MAM and AT; writing of the manuscript, PI, MAM, AMP; critical revision of the manuscript for intellectual content, PI, MAM and RSM. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

   treatment implications for other atypical antipsychotics. J Affect 
15. Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine 
   in patients with bipolar disorder: results from a 2-year mirror-image 
16. Iftene P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P. Rapid 
   clozapine titration in treatment-refractory bipolar disorder. J Affect 
17. Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant 
   bipolar disorder: a systematic review. Bipolar Disord. 2015;17(3): 
   235–247.
18. Bogers JP, Schulte PF, Van Dijk D, Bakker B, Cohen D. Clozapine 
   underutilization in the treatment of schizophrenia: how can clozapine 
   109–111.
20. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for 
   mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 
   429–435.
21. Montgomery SA, Asberg M. A new depression scale designed to be 
22. Spearling MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification 
   of the Clinical Global Impressions (CGI) Scale for use in bipolar 
   illness (BP); the CGI-BP. Psychiatry Res. 1997;73:159–171.
   suicidality in schizophrenia: International Suicide Prevention 
   Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.
24. Kant R, Chalansani R, Chengappa KN, Dieringer MF. The off-label 
   use of clozapine in adolescents with bipolar disorder, intermittent 
   explosive disorder, or posttraumatic stress disorder. J Child Adolesc 
25. Cohen SA, Underwood MT. The use of clozapine in a mentally retarded 
   440–444.
26. Antonacci DJ, de Groot CM. Clozapine treatment in a population of 
27. Frankenburg F, Zanarini M. Clozapine treatment of borderline patients: 
   clozapine in acute and continuation treatment of severe borderline 
29. Beri A, Boydell J. Clozapine in borderline personality disorder: a review 
   Clozapine for treatment-resistant agitation in dementia. J Geriatr 
31. Bastiampillai T, Dhillon R, French TH. Clozapine use in treatment- 
   resistant agitation in the setting of dementia. Aust NZ J Psychiatry. 
   2009;43(7):689–690.
32. Wu CS, Wang SC, Liu SK. Clozapine use reduced psychiatric hospi 
   talization and emergency room visits in patients with bipolar disorder 
   independent of improved treatment regularity in a three-year follow-up 
   psychosis following abrupt clozapine withdrawal. Schizophr Bull. 1996; 